Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy (STARMEN)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Hospital Universitario 12 de Octubre
Sponsor:
Collaborators:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Hospital Universitario Fundación Alcorcón
Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre
Biobanco REDinREN
ERA-EDTA
REDinREN
Sociedad Española de Nefrología
Hospital Universitario de la Princesa
University Hospital, Aachen
Information provided by (Responsible Party):
Manel Praga, MD, Hospital Universitario 12 de Octubre
ClinicalTrials.gov Identifier:
NCT01955187
First received: September 19, 2013
Last updated: August 18, 2016
Last verified: August 2016
  Purpose

In this study, investigators will evaluated the long-term efficacy and safety (two years) of Tacrolimus-Rituximab (RTX) therapy compared to Methylprednisolone-Cyclophosphamide (CYC) therapy in patients with primary Membranous Nephropathy (MN).

PRINCIPAL OBJECTIVE To evaluate whether sequential therapy with tacrolimus leads to a greater increase in the proportion of primary MN patients with Complete or Partial Remission when compared with patients receiving standard treatment. It will be assessed 24 months after the beginning of treatment.

Phase of the trial: and design: Phase III study, open label, randomized, and active controlled trial.

This study will have 3 stages: screening and recruitment of patients for 18 months, treatment period for six months in corticosteroids plus CYC group and 9 months in Tacrolimus-RTX group, and finally post-treatment follow-up period until to complete 24 months of follow-up since initial treatment.

This study will compare the standard therapy for primary MN patients with nephrotic range proteinuria (active control of steroids plus CYC) with a novel sequential therapy of tacrolimus and RTX, an approach of potential high efficacy, low toxicity and more acceptable safety profile.


Condition Intervention Phase
MEMBRANOUS NEPHROPATHY
Drug: TACROLIMUS
Drug: RITUXIMAB
Drug: METHYLPREDNISOLONE
Drug: CYCLOPHOSPHAMIDE
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study)

Resource links provided by NLM:


Further study details as provided by Hospital Universitario 12 de Octubre:

Primary Outcome Measures:
  • Proportion of patients with complete and/or partial remission. [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    The proportion of patients reaching complete remission, defined as a reduction of proteinuria since baseline level to a value equal or lower than 0.5 g/24 h proteinuria plus stable renal function (eGFR ≥ 45 ml/min/1.73m2) or partial remission, defined as a reduction of proteinuria since baseline level to a value less than 3.5 g/24 h and 50% lower than baseline proteinuria plus stable renal function (eGFR ≥ 45 ml/min/1.73m2) at 24 months of study treatment.


Secondary Outcome Measures:
  • Proportion of patients with limited response [ Time Frame: 12, 18, and 24 months ] [ Designated as safety issue: No ]
    The proportion of patients with limited response, defined as a reduction of proteinuria since baseline level > 50% but to a value > 3.5g/24 h. at 12, 18 and 24 months of study treatment.

  • Proportion of patients with increase of baseline serum creatinine ≥ 50% [ Time Frame: 12, 18, and 24 months ] [ Designated as safety issue: No ]
    The number of patients with an increase ≥ 50% of serum creatinine (SCr) from baseline at 12, 18 and 24 months (end of the follow-up).

  • Proportions of patients with relapses [ Time Frame: 9, 12, 18, and 24 months ] [ Designated as safety issue: No ]
    The proportion of patients with relapses (defines as the reappearance of proteinuria > 3.5 gr/24h and at least 50% increase over the lowest baseline value in at least three consecutive visits in those patients who previously presented a PR or CR) and the time to relapse after the treatment period.

  • Proportion of patients with drug-related adverse events [ Time Frame: During all therapy period and until 24 months post-beginning of therapy ] [ Designated as safety issue: Yes ]
    The proportion of patient with drug-related adverse events and serious adverse events.


Estimated Enrollment: 106
Study Start Date: January 2014
Estimated Study Completion Date: April 2019
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sequential therapy: Tacrolimus-Rituximab
Tacrolimus: Initial dose of 0.05 mg/Kg/day PO, adjusted to blood levels (5- 7 ng/ml) for six months. Starting at the end of month 6, tacrolimus will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
Drug: TACROLIMUS
Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
Other Name: TACROLIMUS, ADVAGRAF
Drug: RITUXIMAB
A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction
Other Name: RITUXIMAB, MABTHERA
Active Comparator: Cyclical therapy: Corticosteroids and Cyclophosphamide
Month 1, 3 and 5: 1g IV methylprednisolone daily for three doses, oral methylprednisolone (0.5mg/kg/day) Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
Drug: METHYLPREDNISOLONE
Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.
Other Name: METHYLPREDNISOLONE, URBASON, SOLUMODERIN
Drug: CYCLOPHOSPHAMIDE
Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
Other Name: CYCLOPHOSPHAMIDE, GENOXAL

Detailed Description:

PRIMARY AND SECONDARY ENDPOINTS/OUTCOME MEASURES

Primary end-point:

The proportion of patients reaching CR defined as a reduction of proteinuria since baseline level to a value equal or lower than 0.5 g/24 h proteinuria plus stable renal function (eGFR ≥ 45 ml/min/1.73m2) or PR defined as a reduction of proteinuria since baseline level to a value less than 3.5 g/24 h and 50% lower than baseline proteinuria plus stable renal function (eGFR ≥ 45ml/min/1.73m2) at 24 months of study treatment.

Secondary end-points

  • The proportion of patients with Limited response (LR) defined as a reduction of proteinuria since baseline level > 50% but to a value > 3.5g/24 h. at 12, 18 and 24 months of study treatment..
  • The number of patients with an increase ≥ 50% of serum creatinine (SCr) from baseline at 12, 18 and 24 months (end of the follow-up).
  • The time of renal survival (status free of increase ≥ 50% of baseline SCr) in both arms overall after the study.
  • The proportion of patients with preserved renal function (estimated GFR ≥ 60 ml/min) in both treatment arms after the treatment period.
  • The proportion of patients with relapse (defines as the reappearance of proteinuria > 3.5 gr/24h and at least 50% increase over the lowest baseline value in at least three consecutive visits in those patients who previously presented a PR or CR) and the time to relapse after the treatment period.
  • Serum levels of anti-phospholipase A2 receptor antibodies (anti-PLA2R), before of treatment and at 3, 6, 9, 12, 18 and 24 months of study, in both treatment arms.
  • The proportion of patient with drug-related adverse events and serious adverse events.

STUDY POPULATION

Patients with biopsy-proven idiopathic or primary membranous nephropathy with nephrotic proteinuria and normal or slight decrease of renal function will be enrolled.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients are willing and able to read and correctly understand the patient's information sheet and give their consent for participation in the study (by correctly signing and dating the informed consent form document, which has been previously approved by an Ethics Committee/ International Review Board), before initiating any protocol specific selection procedure.
  • Patients are able to understand study procedures and to comply with them for the entire length of the study.
  • Age older than 18 years.
  • Biopsy-proven primary MN. Patients with nephrotic syndrome relapse after remission (either spontaneous or induced by immunosuppression) can be included without a new renal biopsy, provided that they meet all the other inclusion/exclusion criteria.
  • Estimated GFR ≥ 45 ml/min/1.73m2 in one measurement performed within the screening period (in the 30 days after informed consent signature).
  • Nephrotic-range proteinuria (>4 g/day and not decreasing >50% in the last 6 months) accompanied by hypoalbuminemia ≤ 3, 5 g/dL during the screening period OR patients showing severe or disabling symptoms related to the nephrotic syndrome or severe hypoalbuminemia (<2 g/dL), that can be included before the completion of this 6-month observation period, at the investigator's discretion, independently of proteinuria values.
  • Treatment with an ACEI or ARB for at least 2 months before screening (unless intolerance to ACEI/ARB, contraindications to their use or a low blood pressure that could induce side effects at the investigator's discretion) with a controlled blood pressure for at least the last three months (Mean SBP/DBP ≤ 150/90 mmHg in the last three months).
  • Negative urine pregnancy test for potentially fertile female.

Exclusion Criteria:

  • Diagnosis of secondary causes of membranous nephropathy: malignancy (cancer), systemic infections (which include B and C hepatitis), systemic autoimmune diseases (e.g. Systemic Lupus Erythematosus; SLE) or any other acute or chronic inflammatory disease.
  • HIV infection.
  • Moderate or severe liver disease (AST and ALT > 2.5x upper range limit and total bilirubin > 1.5 x upper range limit).
  • Patients are taking part in any other study with an investigational study and/or are receiving or have received treatment with another investigational drug or intervention (within the first month prior to the signature of the informed consent).
  • Suspected or known hypersensitivity, allergy and/or immunogenic reaction history to either rituximab, cyclosporine, tacrolimus, corticosteroids, CYC or any of their ingredients (which include excipients) and of any other drug from the same pharmacotherapeutic group (i.e. calcineurin inhibitors, specific monoclonal antibodies or alkylating agents).
  • Previous treatment with corticosteroids in the three months period before screening, or previous treatment with other immunosuppressive agent in the six month period before screening.
  • Previous treatment with rituximab or any other biological agent in the two years period before screening.
  • Patients who were non-responders to previous immunosuppressants.
  • Women with a positive pregnancy test at screening or in lactation period or planning to become pregnant within the next 24 months. Women not willing to use contraceptive methods during the complete study period.
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
  • Any other medical unstable, uncontrolled, or severe condition or any other relevant laboratory test finding which, at the investigator's own discretion, could possibly increase the associated risk of the patient's participation in the study.
  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01955187

Contacts
Contact: MANUEL PRAGA, MD mpragat@senefro.org
Contact: JORGE ROJAS, MD jerori2003@yahoo.com

Locations
Spain
Hospital 12 de Octubre Recruiting
Madrid, Spain
Contact: MANUEL PRAGA, MD       mpragat@senefro.org   
Principal Investigator: MANUEL PRAGA, MD         
Sponsors and Collaborators
Hospital Universitario 12 de Octubre
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Hospital Universitario Fundación Alcorcón
Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre
Biobanco REDinREN
ERA-EDTA
REDinREN
Sociedad Española de Nefrología
Hospital Universitario de la Princesa
University Hospital, Aachen
Investigators
Principal Investigator: GEMA FERNÁNDEZ-JUÁREZ, MD Hospital Universitario Fundación Alcorcón, Madrid. Spain
Principal Investigator: JESUS EGIDO, MD, PhD IIS Fundación Jiménez Díaz, Madrid. Spain
Principal Investigator: MARIAN GOICOCHEA, MD Hospital Universitario Gregorio Marañón, Madrid. Spain
Principal Investigator: ALFONS SEGARRA, MD, PhD Hospital Universitari Vall d´Hebron, Barcelona. Spain
Principal Investigator: GUILLERMO MARTÍN, MD Hospital Regional de Málaga, Spain
Principal Investigator: ILDEFONSO VALERA, MD Hospital Virgen de la Victoria de Málaga. Spain
Principal Investigator: VIRGINIA CABELLO, MD Hospital Virgen del Rocío, Sevilla. Spain
Principal Investigator: QUINTANA LUIS, MD Hospital Clinic de Barcelona. Spain
Principal Investigator: CAO MERCEDES, MD Hospital Universitario de A Coruña. Spain
Principal Investigator: AVILA ANA, MD Hospital Dr. Peset, Valencia. Spain
Principal Investigator: ESPINOSA MARIO, MD Hospital Reina Sofía, Córdoba. Spain
Principal Investigator: MONTSERRAT DIAZ, MD Fundación Puigvert, Barcelona. Spain
Principal Investigator: BONET JOSÉ, MD Hospital Germans Trias i Pujol, Barcelona. Spain
Principal Investigator: JUAN RAMÓN GÓMEZ-MARTINO, MD Hospital San Pedro de Alcántara, Cáceres. Spain
Principal Investigator: RIVAS BEGOÑA, MD Hospital Universitario La Paz
Principal Investigator: RODRIGUEZ ANTOLINA, MD Hospital Clínico San Carlos, Madrid. Spain
Principal Investigator: GALEANO CRISTINA, MD Hospital Universitario Ramón y Cajal, Madrid. Spain
Principal Investigator: RIVERA FRANCISCO, MD Hospital de Ciudad Real. Spain
Principal Investigator: WETZELS JACK, MD Radboud University Medical Center. The Netherlands
Principal Investigator: JORGE ROJAS, MD IIS Fundación Jiménez Díaz, Madrid. Spain
  More Information

Responsible Party: Manel Praga, MD, MD, PhD, Hospital Universitario 12 de Octubre
ClinicalTrials.gov Identifier: NCT01955187     History of Changes
Other Study ID Numbers: STARMEN 01-2013  2013-000226-55 
Study First Received: September 19, 2013
Last Updated: August 18, 2016
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Hospital Universitario 12 de Octubre:
SEQUENTIAL THERAPY
PRIMARY MEMBRANOUS NEPHROPATHY
TACROLIMUS
RITUXIMAB

Additional relevant MeSH terms:
Glomerulonephritis, Membranous
Kidney Diseases
Urologic Diseases
Glomerulonephritis
Nephritis
Autoimmune Diseases
Immune System Diseases
Cyclophosphamide
Tacrolimus
Rituximab
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone
Prednisolone hemisuccinate
Prednisolone phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Calcineurin Inhibitors
Enzyme Inhibitors
Anti-Inflammatory Agents
Antiemetics

ClinicalTrials.gov processed this record on September 28, 2016